Forus, formerly known as Tandem, has announced it has raised more than $160 million to accelerate its mission of connecting the fragmented systems that stand between medical breakthroughs and the patients who need them. The New York-based company is backed by Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC. The raise comes as provider adoption of the platform has grown 10 times year-over-year for the past two years, driven entirely by word of mouth.
Forus is an AI-powered network embedded into physician workflows that automates every step between a clinical decision and a patient starting treatment, including insurance authorization, financial assistance, and fulfillment routing. The platform supports every drug, payer, and pharmacy in the country and is free for both doctors and patients. It is currently used by thousands of medical practices and health systems across all 50 states and already supports people in nearly 80% of U.S. residential zip codes, including many patients with complex conditions accessing treatment for the first time. The company said its unique position in the prescription flow gives it unparalleled insight into where providers get stuck, where patients drop off, and how medicines perform across populations — intelligence it makes available to life sciences companies to design better research and launch new medicines more efficiently. Five of the top 10 global biopharma companies are already working with Forus.
The raise addresses a structural gap in the healthcare system that persists despite accelerating scientific progress. Bringing a new drug to market takes 10 to 15 years and costs $2.6 billion on average, and even after FDA approval, too many eligible patients never receive treatment because the infrastructure to deliver modern medicine reliably at scale was never built for its complexity. Forus said its platform creates that missing layer, giving doctors the confidence to prescribe the most effective treatments and giving patients the certainty they will receive them.
KEY QUOTES:
“Drug discovery is moving faster, but the system that turns it into real-world treatment isn’t. We are creating that missing layer. We’re grateful to the clinicians across the country who already trust Forus to get their patients on treatment. There’s an opportunity to unlock an order of magnitude more treatment options for doctors and patients, and we are building a team whose ambition matches that goal.”
Sahir Jaggi, CEO and Founder, Forus
“Too often, patients miss out on the right treatment not because the therapy doesn’t exist, but because the system to deliver it falls short. Forus is addressing this from first principles. By making therapies reliably accessible in practice, they can both improve outcomes today and expand what’s possible in medicine over time.”
Kareem Zaki, Partner, Thrive Capital
